OClawVPS.com
Parkwalk Advisors
Edit

Parkwalk Advisors

http://www.parkwalkadvisors.com
Last activity: 30.03.2026
Active
Invests in categories: TechnologyDataHealthTechSoftwareMedTechHardwarePlatformUniversityEnergyTechIndustry
Parkwalk is one of the UK’s leading growth fund managers backing world-changing technologies emerging out of UK universities and research institutions with the aim of delivering world-class returns.

We back high potential, hard science technology companies that aim to shape the future by commercialising innovation in sectors of strategic importance to UK Plc, such as AI, big data, life science, materials, cleantech, future of mobility, medtech and quantum computing.

Parkwalk currently has over £250m of assets under management. We have invested in over 100 companies across our managed funds, including funds managed in conjunction with the universities of Oxford, Cambridge and Bristol.
In 2017 Parkwalk joined forces with IP Group plc, a FTSE 250 listed company.
News
766
Portfolio
194
Persons
29
Mentions
118
Location: United Kingdom, England, London
Employees: 11-50
Founded date: 2009
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A; Series B; Grant

Portfolio 194

DateNameWebsiteTotal RaisedLocation
09.03.2026Cytotraitcytotrait.com$4.05MUnited Kin...
19.12.2025Riverlaneriverlane.com$233.78MUnited Kin...
29.11.2025Flomarkflomark.co.uk$407.72K-
29.11.2025Nexus Addi...nexus-am.com--
14.11.2025Scripta Th...scriptatherapeutics.com$12.05MUnited Kin...
25.09.2025Trismiktrismik.com$2.97MUnited Kin...
17.09.2025Enhanced G...enhancedgenomics.com$19MUnited Kin...
02.09.2025Phasecraftphasecraft.io$72.24MUnited Kin...
24.07.2025Bitfountbitfount.com$13MUnited Kin...
06.03.2025Sphere Biospherebio.com--
Show more

Persons 29

DateFirst NameLast NameTitleLinkedInLocation
-NeilCameronInvestment...linkedin.c...-
-IanBroadhurstInvestor D...linkedin.c...-
-AmyVirdeeLegal Coun...linkedin.c...-
-CananCelikdemirCompliance...linkedin.c...-
-ClairePardoGeneral Co...linkedin.c...-
-ChloeWoodacreHead of In...linkedin.c...-
-WisdomYemi-Makan...Investment...linkedin.c...-
-EmilieSyedInvestment...linkedin.c...-
-MorayWrightChief Exec...linkedin.c...-
-SamikshaRaiInvestor R...linkedin.c...-
Show more

News 766

DateTitleDescription
06.01.2026Moray Wright features in Professional AdviserFor more than three decades, the Enterprise Investment Scheme has played a significant role in backing founders across the UK. With its expansion at the Budget, it is now positioned to support a far greater number of businesses to scale, no...
09.12.2025Parkwalk Knowledge Intensive EIS Fund V – Now OpenWe are pleased to announce the launch of the Parkwalk Knowledge Intensive EIS Fund V (KI Fund V), an HMRC-approved EIS Fund. The fifth Knowledge Intensive Fund will back cutting-edge technology companies spun out of leading UK universities,...
23.11.2025Parkwalk and IP Group featured in MoneyWeekOur CEO Moray Wright and IP Group’s CEO Greg Smith sat down with MoneyWeek’s Dr Matthew Partridge to discuss the changing landscape for investing in university spinouts, the role of scale-up capital and the big opportunities for investors. ...
13.11.2025Scripta Therapeutics raises $12mWe are pleased to announce our investment in Scripta Therapeutics, a University of Oxford spinout with a novel approach to targeting the aberrant transcriptional networks that drive disease. Oxford, UK: UK techbio startup Scripta Therapeuti...
12.11.2025CamGene announces Seed roundWe are pleased to announce our investment in CamGene, a University of Cambridge spinout advancing first-in-class RNA-based therapies for hearing loss. Cambridge, UK, 3rd November 2025 – CamGene Therapeutics, a pioneering biotech company adv...
12.11.2025Parkwalk named Best EIS Investment Manager 2025We’re pleased to announce that Parkwalk was awarded Best EIS Investment Manager at the 2025 Growth Investor Awards. This recognition reflects our ongoing focus and deep expertise in backing university spinouts and helping founders translate...
14.10.20252025 Beauhurst report on university spinoutsWe are delighted to launch our annual report, Equity Investment into University Spinouts 2025, in conjunction with Beauhurst. Download the full report here Tuesday 14 October 2025, London: A new report published today by Parkwalk, the UK’s ...
02.10.2025NoBACZ Healthcare announces £4.8m funding roundWe are pleased to announce our investment in NoBACZ Healthcare, a University of Cambridge spinout developing innovative “liquid bandage” treatments for horses and livestock. NoBACZ Healthcare, a University of Cambridge spinout developing no...
10.09.2025Applied Systems acquires CytoraWe are delighted to report that Applied Systems has acquired portfolio company Cytora, a spinout from the University of Cambridge, who has developed an AI-powered solution for commercial insurance underwriting. Tuesday 9 September – Applied...
02.09.2025Phasecraft announce $34m Series B funding roundParkwalk are pleased to announce further support for portfolio company Phasecraft, the world’s leading quantum algorithms company and a spinout from UCL. Bristol, London, and Washington D.C., 2nd September 2025: Phasecraft, the world’s lead...
Show more

Mentions in press and media 118

DateTitleDescription
30.03.2026CWOW 2026: Cambridge’s life sciences showcase expands to Oxford & LondonCambridge Wide Open Week (CWOW) returns 11–19 June 2026, sharing the spirit and buzz of the week-long, interactive festival with Oxford and London for the very first time. The Cambridge-Oxford-London corridor is widely regarded as one of th...
10.03.2026Cytotrait Secures £3M: Revolutionizing Crop Traits with MOSS Gene-EditingCytotrait, a cutting-edge biotech firm, secured £3M in seed funding. This capital fuels the advancement of their MOSS technology. MOSS is a proprietary plant gene-editing platform. It precisely modifies chloroplasts and mitochondria. This i...
09.03.2026Cytotrait Raises £3M in Seed FundingCytotrait, a Manchester, UK-based biotechnology company focused on the development of novel traits for food and agriculture, closed £3M seed funding round. The investment was led by Northern Gritstone, with contributions from the UK Innovat...
19.12.2025Riverlane unveils microsecond quantum error decoder-
09.12.2025Parkwalk Knowledge Intensive EIS Fund V – Now OpenWe are pleased to announce the launch of the Parkwalk Knowledge Intensive EIS Fund V (KI Fund V), an HMRC-approved EIS Fund. The fifth Knowledge Intensive Fund will back cutting-edge technology companies spun out of leading UK universities,...
16.11.2025Scripta Therapeutics Transforms Disease Treatment with $12M InvestmentScripta Therapeutics, an Oxford-based techbio startup, has raised $12 million in seed funding. This capital propels its innovative biology-first platform. The system leverages AI, advanced imaging, and patient-derived models. It precisely t...
14.11.2025Scripta Therapeutics Raises $12M in Seed FundingScripta Therapeutics, an Oxford, UK-based techbio startup, raised $12m in seed funding. The round was led by Oxford Science Enterprises and Apollo Health Ventures, with participation from AlbionVC, YZR Capital, and Parkwalk Advisors, and su...
14.11.2025Scripta Therapeutics: $12 Million Closed To Advance Biology-First Drug Discovery Targeting Transcription Factor ActivityScripta Therapeutics, an Oxford-based techbio startup developing disease-modifying drugs that alter transcription factor activity, has emerged from stealth with the announcement of a $12 million seed round. The financing is co-led by Oxford...
12.11.2025The UK’s Scripta Therapeutics raises over €10 million to “flip the script” on drug discoveryOxford BioTech startup Scripta Therapeutics emerges from stealth today by announcing a €10.3 million ($12 million) Seed round to upend conventional approaches to drug discovery. The round is led jointly by Oxford Science Enterprises (OSE) a...
04.11.2025Diffblue’s Latest Innovations in Unit Test Generation Deliver 20x Productivity Advantage Versus AI Coding AssistantsDiffblue today announced the release of the next generation of its flagship product, Diffblue Cover, to address the unmet need for automated, high quality unit test generation at scale. Focused on empowering software development teams to sy...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In